NowComment
2-Pane Combined
Comments:
Full Summaries Sorted

Commenting period (July 15, 2023 20:56 – August 16, 2023 00:00) is closed

ALS-02-v1


0 General Document comments
0 Sentence and Paragraph comments
0 Image and Video comments


RECOVER 2.0 Worksheet

New Thinking Partner Conversation New Conversation
Paragraph 1 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 1, Sentence 1 0
No sentence-level conversations. Start one.

QUESTION ID: ALS-02

New Thinking Partner Conversation New Conversation
Paragraph 2 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 2, Sentence 1 0
No sentence-level conversations. Start one.

PICO Question:
In cats and dogs with a shockable rhythm that are being defibrillated (P), does the use of amiodarone (I) compared to not using amiodarone (C) improve outcome?

New Thinking Partner Conversation New Conversation
Paragraph 3 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 3, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 3, Sentence 2 0
No sentence-level conversations. Start one.

Outcomes:
Favorable neurologic outcome, Surrogate marker(s) of perfusion, Survival to Discharge,ROSC

New Thinking Partner Conversation New Conversation
Paragraph 4 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 4, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 4, Sentence 2 0
No sentence-level conversations. Start one.

Prioritized Outcomes (1= most critical; final number = least important):

New Thinking Partner Conversation New Conversation
Paragraph 5 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 5, Sentence 1 0
No sentence-level conversations. Start one.

1. Favorable neurologic outcome

New Thinking Partner Conversation New Conversation
Paragraph 6 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 6, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 6, Sentence 2 0
No sentence-level conversations. Start one.

2. Survival to discharge

New Thinking Partner Conversation New Conversation
Paragraph 7 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 7, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 7, Sentence 2 0
No sentence-level conversations. Start one.

3. ROSC

New Thinking Partner Conversation New Conversation
Paragraph 8 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 8, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 8, Sentence 2 0
No sentence-level conversations. Start one.

4. Surrogate markers of perfusion

New Thinking Partner Conversation New Conversation
Paragraph 9 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 9, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 9, Sentence 2 0
No sentence-level conversations. Start one.

Domain chairs: Gareth Buckley, Elizabeth Rozanski (Fletcher), Jake Wolf

New Thinking Partner Conversation New Conversation
Paragraph 10 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 10, Sentence 1 0
No sentence-level conversations. Start one.

Evidence evaluators: Alexander Thomson, Joseph DeFulio

New Thinking Partner Conversation New Conversation
Paragraph 11 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 11, Sentence 1 0
No sentence-level conversations. Start one.

Conflicts of interest: None

New Thinking Partner Conversation New Conversation
Paragraph 12 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 12, Sentence 1 0
No sentence-level conversations. Start one.

Search strategy: See attached document

New Thinking Partner Conversation New Conversation
Paragraph 13 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 13, Sentence 1 0
No sentence-level conversations. Start one.

Evidence Review:

New Thinking Partner Conversation New Conversation
Paragraph 14 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 14, Sentence 1 0
No sentence-level conversations. Start one.

Study Design

New Thinking Partner Conversation New Conversation
Paragraph 15 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 15, Sentence 1 0
No sentence-level conversations. Start one.

Reduced Quality Factors

New Thinking Partner Conversation New Conversation
Paragraph 16 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 16, Sentence 1 0
No sentence-level conversations. Start one.

0 = no serious, - = serious,

New Thinking Partner Conversation New Conversation
Paragraph 17 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 17, Sentence 1 0
No sentence-level conversations. Start one.

- - = very serious

New Thinking Partner Conversation New Conversation
Paragraph 18 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 18, Sentence 1 0
No sentence-level conversations. Start one.

Positive Quality Factors

New Thinking Partner Conversation New Conversation
Paragraph 19 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 19, Sentence 1 0
No sentence-level conversations. Start one.

0 = none, + = one, ++ = multiple

New Thinking Partner Conversation New Conversation
Paragraph 20 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 20, Sentence 1 0
No sentence-level conversations. Start one.

Dichotomous Outcome Summary

New Thinking Partner Conversation New Conversation
Paragraph 21 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 21, Sentence 1 0
No sentence-level conversations. Start one.

Non-Dichotomous Outcome Summary

New Thinking Partner Conversation New Conversation
Paragraph 22 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 22, Sentence 1 0
No sentence-level conversations. Start one.

Brief description

New Thinking Partner Conversation New Conversation
Paragraph 23 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 23, Sentence 1 0
No sentence-level conversations. Start one.

Overall Quality

New Thinking Partner Conversation New Conversation
Paragraph 24 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 24, Sentence 1 0
No sentence-level conversations. Start one.

High, moderate, low,
very low, none

New Thinking Partner Conversation New Conversation
Paragraph 25 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 25, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 25, Sentence 2 0
No sentence-level conversations. Start one.

No of studies

New Thinking Partner Conversation New Conversation
Paragraph 26 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 26, Sentence 1 0
No sentence-level conversations. Start one.

Study Type

New Thinking Partner Conversation New Conversation
Paragraph 27 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 27, Sentence 1 0
No sentence-level conversations. Start one.

RoB

New Thinking Partner Conversation New Conversation
Paragraph 28 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 28, Sentence 1 0
No sentence-level conversations. Start one.

Indirectness

New Thinking Partner Conversation New Conversation
Paragraph 29 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 29, Sentence 1 0
No sentence-level conversations. Start one.

Imprecision

New Thinking Partner Conversation New Conversation
Paragraph 30 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 30, Sentence 1 0
No sentence-level conversations. Start one.

Inconsistency

New Thinking Partner Conversation New Conversation
Paragraph 31 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 31, Sentence 1 0
No sentence-level conversations. Start one.

Large Effect

New Thinking Partner Conversation New Conversation
Paragraph 32 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 32, Sentence 1 0
No sentence-level conversations. Start one.

Dose-Response

New Thinking Partner Conversation New Conversation
Paragraph 33 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 33, Sentence 1 0
No sentence-level conversations. Start one.

Confounder

New Thinking Partner Conversation New Conversation
Paragraph 34 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 34, Sentence 1 0
No sentence-level conversations. Start one.

# Intervention with Outcome

New Thinking Partner Conversation New Conversation
Paragraph 35 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 35, Sentence 1 0
No sentence-level conversations. Start one.

# Control with Outcome

New Thinking Partner Conversation New Conversation
Paragraph 36 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 36, Sentence 1 0
No sentence-level conversations. Start one.

RR (95% CI)

New Thinking Partner Conversation New Conversation
Paragraph 37 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 37, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: Favorable neurologic outcome

New Thinking Partner Conversation New Conversation
Paragraph 38 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 38, Sentence 1 0
No sentence-level conversations. Start one.

3

New Thinking Partner Conversation New Conversation
Paragraph 39 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 39, Sentence 1 0
No sentence-level conversations. Start one.

CT

New Thinking Partner Conversation New Conversation
Paragraph 40 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 40, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 41 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 41, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 42 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 42, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 43 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 43, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 44 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 44, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 45 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 45, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 46 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 46, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 47 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 47, Sentence 1 0
No sentence-level conversations. Start one.

Moderate

New Thinking Partner Conversation New Conversation
Paragraph 48 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 48, Sentence 1 0
No sentence-level conversations. Start one.

2

New Thinking Partner Conversation New Conversation
Paragraph 49 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 49, Sentence 1 0
No sentence-level conversations. Start one.

OS

New Thinking Partner Conversation New Conversation
Paragraph 50 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 50, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 51 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 51, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 52 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 52, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 53 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 53, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 54 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 54, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 55 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 55, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 56 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 56, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 57 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 57, Sentence 1 0
No sentence-level conversations. Start one.

Very low

New Thinking Partner Conversation New Conversation
Paragraph 58 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 58, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 59 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 59, Sentence 1 0
No sentence-level conversations. Start one.

ES

New Thinking Partner Conversation New Conversation
Paragraph 60 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 60, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: Survival to discharge

New Thinking Partner Conversation New Conversation
Paragraph 61 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 61, Sentence 1 0
No sentence-level conversations. Start one.

3

New Thinking Partner Conversation New Conversation
Paragraph 62 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 62, Sentence 1 0
No sentence-level conversations. Start one.

CT

New Thinking Partner Conversation New Conversation
Paragraph 63 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 63, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 64 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 64, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 65 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 65, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 66 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 66, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 67 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 67, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 68 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 68, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 69 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 69, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 70 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 70, Sentence 1 0
No sentence-level conversations. Start one.

Moderate

New Thinking Partner Conversation New Conversation
Paragraph 71 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 71, Sentence 1 0
No sentence-level conversations. Start one.

8

New Thinking Partner Conversation New Conversation
Paragraph 72 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 72, Sentence 1 0
No sentence-level conversations. Start one.

OS

New Thinking Partner Conversation New Conversation
Paragraph 73 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 73, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 74 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 74, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 75 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 75, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 76 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 76, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 77 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 77, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 78 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 78, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 79 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 79, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 80 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 80, Sentence 1 0
No sentence-level conversations. Start one.

Low

New Thinking Partner Conversation New Conversation
Paragraph 81 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 81, Sentence 1 0
No sentence-level conversations. Start one.

4

New Thinking Partner Conversation New Conversation
Paragraph 82 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 82, Sentence 1 0
No sentence-level conversations. Start one.

ES

New Thinking Partner Conversation New Conversation
Paragraph 83 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 83, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 84 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 84, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 85 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 85, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 86 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 86, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 87 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 87, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 88 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 88, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 89 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 89, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 90 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 90, Sentence 1 0
No sentence-level conversations. Start one.

Low

New Thinking Partner Conversation New Conversation
Paragraph 91 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 91, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: ROSC

New Thinking Partner Conversation New Conversation
Paragraph 92 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 92, Sentence 1 0
No sentence-level conversations. Start one.

1

New Thinking Partner Conversation New Conversation
Paragraph 93 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 93, Sentence 1 0
No sentence-level conversations. Start one.

CT

New Thinking Partner Conversation New Conversation
Paragraph 94 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 94, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 95 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 95, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 96 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 96, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 97 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 97, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 98 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 98, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 99 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 99, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 100 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 100, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 101 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 101, Sentence 1 0
No sentence-level conversations. Start one.

Moderate

New Thinking Partner Conversation New Conversation
Paragraph 102 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 102, Sentence 1 0
No sentence-level conversations. Start one.

2

New Thinking Partner Conversation New Conversation
Paragraph 103 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 103, Sentence 1 0
No sentence-level conversations. Start one.

OS

New Thinking Partner Conversation New Conversation
Paragraph 104 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 104, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 105 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 105, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 106 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 106, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 107 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 107, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 108 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 108, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 109 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 109, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 110 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 110, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 111 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 111, Sentence 1 0
No sentence-level conversations. Start one.

Very low

New Thinking Partner Conversation New Conversation
Paragraph 112 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 112, Sentence 1 0
No sentence-level conversations. Start one.

7

New Thinking Partner Conversation New Conversation
Paragraph 113 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 113, Sentence 1 0
No sentence-level conversations. Start one.

ES

New Thinking Partner Conversation New Conversation
Paragraph 114 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 114, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 115 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 115, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 116 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 116, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 117 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 117, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 118 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 118, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 119 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 119, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 120 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 120, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 121 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 121, Sentence 1 0
No sentence-level conversations. Start one.

Very low

New Thinking Partner Conversation New Conversation
Paragraph 122 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 122, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: Surrogate markers of perfusion

New Thinking Partner Conversation New Conversation
Paragraph 123 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 123, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 124 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 124, Sentence 1 0
No sentence-level conversations. Start one.

CT

New Thinking Partner Conversation New Conversation
Paragraph 125 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 125, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 126 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 126, Sentence 1 0
No sentence-level conversations. Start one.

OS

New Thinking Partner Conversation New Conversation
Paragraph 127 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 127, Sentence 1 0
No sentence-level conversations. Start one.

11

New Thinking Partner Conversation New Conversation
Paragraph 128 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 128, Sentence 1 0
No sentence-level conversations. Start one.

ES

New Thinking Partner Conversation New Conversation
Paragraph 129 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 129, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 130 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 130, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 131 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 131, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 132 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 132, Sentence 1 0
No sentence-level conversations. Start one.

-

New Thinking Partner Conversation New Conversation
Paragraph 133 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 133, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 134 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 134, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 135 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 135, Sentence 1 0
No sentence-level conversations. Start one.

0

New Thinking Partner Conversation New Conversation
Paragraph 136 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 136, Sentence 1 0
No sentence-level conversations. Start one.

Very low

New Thinking Partner Conversation New Conversation
Paragraph 137 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 137, Sentence 1 0
No sentence-level conversations. Start one.

PICO Question Summary

New Thinking Partner Conversation New Conversation
Paragraph 138 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 138, Sentence 1 0
No sentence-level conversations. Start one.

Introduction

New Thinking Partner Conversation New Conversation
Paragraph 139 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 139, Sentence 1 0
No sentence-level conversations. Start one.

The gold-standard for treatment of PVT and VF is basic life support and defibrillation. However, the role of adjunctive therapies for shock-resistant PVT or VF is unclear. Current veterinary guidelines state that in dogs with shock-resistant PVT or VF, amiodarone may be considered.1 In human medicine, the role of antiarrhythmics (amiodarone, lidocaine, bretylium, nifekalant, etc.) during CPR remains unclear. This PICO question investigated whether amiodarone is efficacious as adjunctive therapy in dogs and cats with shockable arrest rhythms.

New Thinking Partner Conversation New Conversation
Paragraph 140 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 140, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 140, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 140, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 140, Sentence 4 0
No sentence-level conversations. Start one.

Consensus on science

New Thinking Partner Conversation New Conversation
Paragraph 141 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 141, Sentence 1 0
No sentence-level conversations. Start one.

Outcome 1: Favorable neurologic outcome

New Thinking Partner Conversation New Conversation
Paragraph 142 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 142, Sentence 1 0
No sentence-level conversations. Start one.

For the most critical outcome of favorable neurologic outcome, 3 clinical trials in adult humans (moderate quality of evidence downgraded for serious indirectness) and 2 observational studies, one in children and one in adult humans, were identified (very low quality of evidence downgraded for serious indirectness and imprecision).2–6 The clinical trials were double-blinded and evaluated adults with non-traumatic out-of-hospital cardiac arrest and shock-refractory VF or PVT (defined as persistent or recurrent shockable rhythms after one or more shocks anytime during resuscitation). Patients were randomized to receive amiodarone, lidocaine, or placebo following vasopressor administration. Neither amiodarone nor lidocaine resulted in a more favorable neurologic outcome compared to placebo.2–4 The observational studies found no difference between lidocaine and amiodarone for favorable neurologic outcome with refractory PVT or VF; however, no control group was used in these studies.5,6 One study showed increased defibrillation success after 3 shocks in patients receiving amiodarone compared to patients receiving lidocaine.6

New Thinking Partner Conversation New Conversation
Paragraph 143 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 143, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 143, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 143, Sentence 3 0
No sentence-level conversations. Start one.

Outcome 2: Survival to discharge

New Thinking Partner Conversation New Conversation
Paragraph 144 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 144, Sentence 1 0
No sentence-level conversations. Start one.

For the second most critical outcome of survival to discharge, the same 3 clinical trials in adults were identified. In addition, 8 observational studies in humans (very low quality of evidence downgraded for serious indirectness) and four experimental studies in pigs (low quality of evidence downgraded for serious indirectness and imprecision) were identified.5–16 One of the clinical trials showed that for witnessed arrests, patients administered lidocaine or amiodarone had significantly higher survival to discharge when compared to placebo.3 Additionally, lidocaine and amiodarone recipients required fewer shocks, but there was no difference in survival to discharge.2 Furthermore, one study showed that amiodarone or lidocaine administered intravenously, but not intraosseously, was associated with significantly improved survival to discharge compared to placebo.4 Many of the observational studies lacked a control population, complicating their interpretation. Many of these studies compared antiarrhythmics to one another (lidocaine versus amiodarone, nifekalant versus amiodarone); the majority found no difference in survival to discharge between different antiarrhythmics. Interestingly, in a study of adults with non-traumatic cardiac arrest, Huang et al. found that survival to ICU admission, survival to discharge, and 1-year survival were highest when patients with refractory shockable rhythms were given both lidocaine and amiodarone.12 Survival to discharge was less likely in those only administered amiodarone, lower still in those only administered lidocaine, and lowest in those receiving neither. Ji et al. demonstrated higher ROSC and 24 hour survival, decreased number of shocks, lower defibrillation energy, epinephrine dose, and duration of CPR in pigs with refractory shockable rhythms administered amiodarone or nifekalant when compared to saline.13 Similarly, Zoerner et al. found greater 3-hour survival in pigs administered amiodarone in a hemorrhagic shock VF model.16 However, Karlis et al. found higher survival with nifekalant compared to amiodarone and saline and no difference in 48 hour survival between the control and amiodarone groups.15 Similarly, Glover et al. found no difference in survival between amiodarone and placebo. 14

New Thinking Partner Conversation New Conversation
Paragraph 145 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 145, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 145, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 145, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 145, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 145, Sentence 5 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 145, Sentence 6 0
No sentence-level conversations. Start one.

Outcome 3: ROSC

New Thinking Partner Conversation New Conversation
Paragraph 146 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 146, Sentence 1 0
No sentence-level conversations. Start one.

For the next most important outcome of ROSC, we evaluated 1 clinical trial (low quality of evidence, downgraded for serious indirectness), 2 observational studies (very low quality of evidence, downgraded for serious indirectness) and 7 experimental studies (very low quality of evidence, downgraded for serious indirectness, serious imprecision, and serious inconsistency), 3 in dogs and 4 in swine. The clinical trial and 2 observational studies showed no difference in frequency of ROSC with the use of amiodarone in patients with refractory shockable rhythms.2,7,8 The experimental studies had heterogenous study designs, but overall 1 of 4 swine studies and 2 of 3 canine studies showed improvement in the frequency of ROSC in animals receiving amiodarone.13,17,18 The remainder of the studies showed no difference in ROSC between the amiodarone and control groups.15,16,19,20

New Thinking Partner Conversation New Conversation
Paragraph 147 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 147, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 147, Sentence 2 0
No sentence-level conversations. Start one.

Outcome 4: Surrogate markers of perfusion

New Thinking Partner Conversation New Conversation
Paragraph 148 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 148, Sentence 1 0
No sentence-level conversations. Start one.

For the outcome of surrogate markers of perfusion, 9 experimental studies were identified (very low quality of evidence, downgraded for serious indirectness, imprecision, and inconsistency). It is important to note that multiple experimental studies demonstrated lower coronary perfusion pressure in dogs and pigs administered amiodarone in the absence of concurrent vasopressor therapy13,18,19 The vasodilatory effects of amiodarone may be reduced when epinephrine is administered concurrently with amiodarone.17 It should also be noted that IV amiodarone does not appear to increase the defibrillation threshold, unlike oral amiodarone.21,22 Of the 9 studies, 4 were in dogs. Two showed improvement in surrogate markers of perfusion in dogs with refractory shockable rhythms with the addition of amiodarone, 1 showed no difference, and 1 showed worsened surrogate markers of perfusion.17–19,23

New Thinking Partner Conversation New Conversation
Paragraph 149 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 149, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 149, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 149, Sentence 3 0
No sentence-level conversations. Start one.

Treatment recommendation

New Thinking Partner Conversation New Conversation
Paragraph 150 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 150, Sentence 1 0
No sentence-level conversations. Start one.

If lidocaine is unavailable, we suggest that amiodarone may be administered intravenously (5 mg/kg) during CPR for PVT or VF refractory to the first shock in dogs (weak recommendation, very low quality of evidence).

New Thinking Partner Conversation New Conversation
Paragraph 151 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 151, Sentence 1 0
No sentence-level conversations. Start one.

We suggest that amiodarone may be administered intravenously (5 mg/kg) during CPR for PVT or VF refractory to the first shock in cats (weak recommendation, very low quality of evidence).

New Thinking Partner Conversation New Conversation
Paragraph 152 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 152, Sentence 1 0
No sentence-level conversations. Start one.

We recommend against the use of amiodarone formulations containing polysorbate-80 in dogs due to the adverse hemodynamic side effects of these formulations that have been documented (strong recommendation, moderate quality of evidence).

New Thinking Partner Conversation New Conversation
Paragraph 153 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 153, Sentence 1 0
No sentence-level conversations. Start one.

Justification of treatment recommendation

New Thinking Partner Conversation New Conversation
Paragraph 154 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 154, Sentence 1 0
No sentence-level conversations. Start one.

Clinical trials and observational studies in people and experimental studies in pigs and dogs found conflicting results for the efficacy of amiodarone for the treatment of refractory PVT and VF. Many of the observational studies lacked a placebo group (instead comparing lidocaine to amiodarone therapy), complicating their interpretation. There is very little evidence suggesting that amiodarone is superior to lidocaine in these studies. The evidence of profound adverse hemodynamic effects in dogs of amiodarone formulations containing polysorbate-80 indicates that these formulations should not be used during CPR in dogs.24 The alternative aqueous formulations of amiodarone are reportedly safer25, but they are pre-diluted to a low concentration, requiring infusion of large volumes (approximately 3.3 ml/kg) to achieve the recommended dose, which may be impractical during CPR. There is one case report of successful treatment of VT in a cat using the aqueous formulation of amiodarone.26 For these reasons, the committee suggests that amiodarone can be used for dogs and cats with PVT or VF refractory to an initial attempt at defibrillation, but if lidocaine is available, it is the more practical and safer drug in dogs.

New Thinking Partner Conversation New Conversation
Paragraph 155 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 155, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 155, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 155, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 155, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 155, Sentence 5 0
No sentence-level conversations. Start one.

Knowledge gaps

New Thinking Partner Conversation New Conversation
Paragraph 156 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 156, Sentence 1 0
No sentence-level conversations. Start one.

There are no controlled studies evaluating amiodarone administration in dogs and cats with spontaneous CPA and amiodarone has not been evaluated in cats. The optimal timing and dosage for amiodarone administration during CPR is unknown. Additionally, whether amiodarone should be administered concurrently with lidocaine to improve outcomes is unknown. Compared to human medicine, shockable rhythms in veterinary medicine appear less common.[ Hohene, in press] Therefore, the role of amiodarone for management of refractory pVT or VF is considered a low-priority knowledge gap in the veterinary literature.

New Thinking Partner Conversation New Conversation
Paragraph 157 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 157, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 157, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 157, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 157, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 157, Sentence 5 0
No sentence-level conversations. Start one.

References:

New Thinking Partner Conversation New Conversation
Paragraph 158 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 158, Sentence 1 0
No sentence-level conversations. Start one.

1. Fletcher DJ, Boller M, Brainard BM, et al. RECOVER evidence and knowledge gap analysis on veterinary CPR. Part 7: Clinical guidelines: RECOVER clinical guidelines. J Vet Emerg Crit Care. 2012;22(s1):S102-S131.

New Thinking Partner Conversation New Conversation
Paragraph 159 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 159, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 159, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 159, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 159, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 159, Sentence 5 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 159, Sentence 6 0
No sentence-level conversations. Start one.

2. Kudenchuk PJ, Leroux BG, Daya M, et al. Antiarrhythmic Drugs for Nonshockable-Turned-Shockable Out-of-Hospital Cardiac Arrest: The ALPS Study (Amiodarone, Lidocaine, or Placebo). Circulation. 2017;136(22):2119-2131.

New Thinking Partner Conversation New Conversation
Paragraph 160 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 160, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 160, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 160, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 160, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 160, Sentence 5 0
No sentence-level conversations. Start one.

3. Kudenchuk PJ, Brown SP, Daya M, et al. Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. N Engl J Med. 2016;374(18):1711-1722.

New Thinking Partner Conversation New Conversation
Paragraph 161 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 161, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 161, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 161, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 161, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 161, Sentence 5 0
No sentence-level conversations. Start one.

4. Daya MR, Leroux BG, Dorian P, et al. Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest. Circulation. 2020;141(3):188-198.

New Thinking Partner Conversation New Conversation
Paragraph 162 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 162, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 162, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 162, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 162, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 162, Sentence 5 0
No sentence-level conversations. Start one.

5. Holmberg MJ, Ross CE, Atkins DL, et al. Lidocaine versus amiodarone for pediatric in-hospital cardiac arrest: An observational study. Resuscitation. 2020;149:191-201.

New Thinking Partner Conversation New Conversation
Paragraph 163 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 163, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 163, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 163, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 163, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 163, Sentence 5 0
No sentence-level conversations. Start one.

6. Wang CH, Chang WT, Huang CH, et al. Outcomes associated with amiodarone and lidocaine for the treatment of adult in-hospital cardiac arrest with shock-refractory pulseless ventricular tachyarrhythmia. J Formos Med Assoc. 2020;119(1 Pt 2):327-334.

New Thinking Partner Conversation New Conversation
Paragraph 164 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 164, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 164, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 164, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 164, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 164, Sentence 5 0
No sentence-level conversations. Start one.

7. Valdes SO, Donoghue AJ, Hoyme DB, et al. Outcomes associated with amiodarone and lidocaine in the treatment of in-hospital pediatric cardiac arrest with pulseless ventricular tachycardia or ventricular fibrillation. Resuscitation. 2014;85(3):381-386.

New Thinking Partner Conversation New Conversation
Paragraph 165 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 165, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 165, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 165, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 165, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 165, Sentence 5 0
No sentence-level conversations. Start one.

8. Pollak PT, Wee V, Al-Hazmi A, Martin J, Zarnke KB. The use of amiodarone for in-hospital cardiac arrest at two tertiary care centres. Can J Cardiol. 2006;22(3):199-202.

New Thinking Partner Conversation New Conversation
Paragraph 166 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 166, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 166, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 166, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 166, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 166, Sentence 5 0
No sentence-level conversations. Start one.

9. Amino M, Inokuchi S, Nagao K, et al. Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study. J Cardiovasc Pharmacol. 2015;66(6):600-609.

New Thinking Partner Conversation New Conversation
Paragraph 167 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 167, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 167, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 167, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 167, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 167, Sentence 5 0
No sentence-level conversations. Start one.

10. Tagami T, Matsui H, Tanaka C, et al. Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. Cardiovasc Drugs Ther. 2016;30(5):485-491.

New Thinking Partner Conversation New Conversation
Paragraph 168 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 168, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 168, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 168, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 168, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 168, Sentence 5 0
No sentence-level conversations. Start one.

11. Tagami T, Matsui H, Ishinokami S, et al. Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. Resuscitation. 2016;109:127-132.

New Thinking Partner Conversation New Conversation
Paragraph 169 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 169, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 169, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 169, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 169, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 169, Sentence 5 0
No sentence-level conversations. Start one.

12. Huang CH, Yu PH, Tsai MS, et al. Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: A nationwide cohort study. Int J Cardiol. 2017;227:292-298.

New Thinking Partner Conversation New Conversation
Paragraph 170 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 170, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 170, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 170, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 170, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 170, Sentence 5 0
No sentence-level conversations. Start one.

13. Ji XF, Li CS, Wang S, Yang L, Cong LH. Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest. Resuscitation. 2010;81(8):1031-1036.

New Thinking Partner Conversation New Conversation
Paragraph 171 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 171, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 171, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 171, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 171, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 171, Sentence 5 0
No sentence-level conversations. Start one.

14. Glover BM, Hu X, Aves T, et al. Dronedarone and captisol-enabled amiodarone in an experimental cardiac arrest. J Cardiovasc Pharmacol. 2013;61(5):385-390.

New Thinking Partner Conversation New Conversation
Paragraph 172 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 172, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 172, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 172, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 172, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 172, Sentence 5 0
No sentence-level conversations. Start one.

15. Karlis G, Iacovidou N, Lelovas P, et al. Nifekalant Versus Amiodarone in the Treatment of Cardiac Arrest: an Experimental Study in a Swine Model of Prolonged Ventricular Fibrillation. Cardiovasc Drugs Ther. 2015;29(5):425-431.

New Thinking Partner Conversation New Conversation
Paragraph 173 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 173, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 173, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 173, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 173, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 173, Sentence 5 0
No sentence-level conversations. Start one.

16. Zoerner F, Semenas E. Resuscitation with amiodarone increases survival after hemorrhage and ventricular fibrillation in pigs. J Trauma Acute Care Surg. 2014;76(6):1402-1408.

New Thinking Partner Conversation New Conversation
Paragraph 174 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 174, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 174, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 174, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 174, Sentence 4 0
No sentence-level conversations. Start one.

17. Wira C, Martin G, Stoner J, Margolis K, Donnino M. Application of normothermic cardiac arrest algorithms to hypothermic cardiac arrest in a canine model. Resuscitation. 2006;69(3):509-516.

New Thinking Partner Conversation New Conversation
Paragraph 175 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 175, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 175, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 175, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 175, Sentence 4 0
No sentence-level conversations. Start one.

18. Anastasiou-Nana MI, Nanas JN, Nanas SN, et al. Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. J Am Coll Cardiol. 1994;23(1):253-258.

New Thinking Partner Conversation New Conversation
Paragraph 176 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 176, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 176, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 176, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 176, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 176, Sentence 5 0
No sentence-level conversations. Start one.

19. Stoner J, Martin G, O’Mara K, Ehlers J, Tomlanovich M. Amiodarone and bretylium in the treatment of hypothermic ventricular fibrillation in a canine model. Acad Emerg Med. 2003;10(3):187-191.

New Thinking Partner Conversation New Conversation
Paragraph 177 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 177, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 177, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 177, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 177, Sentence 4 0
No sentence-level conversations. Start one.

20. Wiesmann T, Freitag D, Dersch W, et al. Dantrolene versus amiodarone for cardiopulmonary resuscitation: A randomized, double-blinded experimental study. Sci Rep. 2017;7.

New Thinking Partner Conversation New Conversation
Paragraph 178 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 178, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 178, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 178, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 178, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 178, Sentence 5 0
No sentence-level conversations. Start one.

21. FRAME LH. The Effect of Chronic Oral and Acute Intravenous Amiodarone Administration on Ventricular Defibrillation Threshold Using Implanted Electrodes in Dogs. Pacing Clin Electrophysiol. 1989;12(2):339-346.

New Thinking Partner Conversation New Conversation
Paragraph 179 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 179, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 179, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 179, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 179, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 179, Sentence 5 0
No sentence-level conversations. Start one.

22. Fain ES, Lee JT, Winkle RA. Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. Am Heart J. 1987;114(1 PART 1):8-17.

New Thinking Partner Conversation New Conversation
Paragraph 180 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 180, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 180, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 180, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 180, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 180, Sentence 5 0
No sentence-level conversations. Start one.

23. Arredondo MT, Guillen SG, Quinteiro RA. Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions. Eur J Pharmacol. 1986;125(1):23-28.

New Thinking Partner Conversation New Conversation
Paragraph 181 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 181, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 181, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 181, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 181, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 181, Sentence 5 0
No sentence-level conversations. Start one.

24. Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions. 1985;16(6):470-477.

New Thinking Partner Conversation New Conversation
Paragraph 182 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 182, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 182, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 182, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 182, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 182, Sentence 5 0
No sentence-level conversations. Start one.

25. Levy NA, Koenigshof AM, Sanders RA. Retrospective evaluation of intravenous premixed amiodarone use and adverse effects in dogs (17 cases: 2011-2014). J Vet Cardiol Off J Eur Soc Vet Cardiol. 2016;18(1):10-14.

New Thinking Partner Conversation New Conversation
Paragraph 183 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 183, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 183, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 183, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 183, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 183, Sentence 5 0
No sentence-level conversations. Start one.

26. Berlin N, Ohad DG, Maiorkis I, Kelmer E. Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. J Vet Emerg Crit Care San Antonio. Published online 2020.

New Thinking Partner Conversation New Conversation
Paragraph 184 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 184, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 184, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 184, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 184, Sentence 4 0
No sentence-level conversations. Start one.

Additional References:

New Thinking Partner Conversation New Conversation
Paragraph 185 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 185, Sentence 1 0
No sentence-level conversations. Start one.

Masini E, Planchenault J, Pezziardi F, Gautier P, Gagnol JP. Histamine-releasing properties of Polysorbate 80 in vitro and in vivo: correlation with its hypotensive action in the dog. Agents Actions. 1985; 16: 470–477.

New Thinking Partner Conversation New Conversation
Paragraph 186 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 186, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 186, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 186, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 186, Sentence 4 0
No sentence-level conversations. Start one.

Levy NA, Koenigshof AM, Sanders RA. Retrospective evaluation of intravenous premixed amiodarone use and adverse effects in dogs (17 cases: 2011-2014). J Vet Cardiol. 2016 Mar;18(1):10-4. doi: 10.1016/j.jvc.2015.10.009. Epub 2016 Jan 21. PMID: 26803199.

New Thinking Partner Conversation New Conversation
Paragraph 187 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 187, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 187, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 187, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 187, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 187, Sentence 5 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 187, Sentence 6 0
No sentence-level conversations. Start one.

Berlin N, Ohad DG, Maiorkis I, Kelmer E. Successful management of ventricular fibrillation and ventricular tachycardia using defibrillation and intravenous amiodarone therapy in a cat. J Vet Emerg Crit Care (San Antonio). 2020 Jul;30(4):474-480. doi: 10.1111/vec.12960. Epub 2020 May 13. PMID: 32400960

New Thinking Partner Conversation New Conversation
Paragraph 188 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 188, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 188, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 188, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 188, Sentence 4 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 188, Sentence 5 0
No sentence-level conversations. Start one.

Supplemental Information:

New Thinking Partner Conversation New Conversation
Paragraph 189 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 189, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: Favorable neurologic outcome

New Thinking Partner Conversation New Conversation
Paragraph 190 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 190, Sentence 1 0
No sentence-level conversations. Start one.

3 Clinical Trials

New Thinking Partner Conversation New Conversation
Paragraph 191 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 191, Sentence 1 0
No sentence-level conversations. Start one.

Kudenchuk et al., 2016: Amiodarone, lidocaine, or placebo in OOHCA

New Thinking Partner Conversation New Conversation
Paragraph 192 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 192, Sentence 1 0
No sentence-level conversations. Start one.

Randomized, double blind trial of adults with non-traumatic OOHCA and shock refractory VF or PVT (shock refractory: persistent or recurrent shockable rhythm after one or more shocks anytime during resuscitation)

New Thinking Partner Conversation New Conversation
Paragraph 193 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 193, Sentence 1 0
No sentence-level conversations. Start one.

Patients then randomized to receive amiodarone, lidocaine, or placebo after a vasopressor

New Thinking Partner Conversation New Conversation
Paragraph 194 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 194, Sentence 1 0
No sentence-level conversations. Start one.

Neither amiodarone nor lidocaine resulted in a higher survivor or favorable neuro outcome than placebo

New Thinking Partner Conversation New Conversation
Paragraph 195 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 195, Sentence 1 0
No sentence-level conversations. Start one.

With witnessed arrest, lidocaine and amiodarone had significantly higher survival than placebo

New Thinking Partner Conversation New Conversation
Paragraph 196 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 196, Sentence 1 0
No sentence-level conversations. Start one.

Kudenchuk et al., 2017: Antiarrhythmic drugs for nonshockable turned shockable OOHCA

New Thinking Partner Conversation New Conversation
Paragraph 197 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 197, Sentence 1 0
No sentence-level conversations. Start one.

Adults with nontraumatic OOHCA and VF/PVT anytime after one or more shocks randomized to placebo, lidocaine, or amiodarone

New Thinking Partner Conversation New Conversation
Paragraph 198 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 198, Sentence 1 0
No sentence-level conversations. Start one.

3026 with VF/PVT and 1063 with nonshockable turned shockable

New Thinking Partner Conversation New Conversation
Paragraph 199 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 199, Sentence 1 0
No sentence-level conversations. Start one.

Non-statistically significant increase in survival (and improved neuro outcome) with amiodarone or lidocaine compared to placebo

New Thinking Partner Conversation New Conversation
Paragraph 200 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 200, Sentence 1 0
No sentence-level conversations. Start one.

Active-drug recipients in this cohort required fewer shocks, supplemental doses of their assigned drug, and ancillary antiarrhythmic drugs than recipients of a placebo

New Thinking Partner Conversation New Conversation
Paragraph 201 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 201, Sentence 1 0
No sentence-level conversations. Start one.

Survival approached significance (p 0.08) for nonshockable turned shockable rhythms with amiodarone compared to placebo

New Thinking Partner Conversation New Conversation
Paragraph 202 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 202, Sentence 1 0
No sentence-level conversations. Start one.

Daye et al., 2020: Survival after IV versus IO amiodarone, lidocaine, or placebo in OOH shock-refractory cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 203 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 203, Sentence 1 0
No sentence-level conversations. Start one.

Same study population as previous study

New Thinking Partner Conversation New Conversation
Paragraph 204 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 204, Sentence 1 0
No sentence-level conversations. Start one.

Amiodarone and lidocaine associated with more favorable neuro outcome when administered IV, but not IO when compared to placebo (as was survival to discharge and survival to hospital admission)

New Thinking Partner Conversation New Conversation
Paragraph 205 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 205, Sentence 1 0
No sentence-level conversations. Start one.

2 Observational Studies

New Thinking Partner Conversation New Conversation
Paragraph 206 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 206, Sentence 1 0
No sentence-level conversations. Start one.

Holmberg et al., 2020: Lidocaine versus amiodarone for pediatric in hospital cardiac arrest: an observational study

New Thinking Partner Conversation New Conversation
Paragraph 207 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 207, Sentence 1 0
No sentence-level conversations. Start one.

From registry, included children with IHCA with an initial or subsequent shockable rhythm and then matched based on a propensity score

New Thinking Partner Conversation New Conversation
Paragraph 208 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 208, Sentence 1 0
No sentence-level conversations. Start one.

No difference between lidocaine and amiodarone for survival, ROSC, or favorable neuro outcome

New Thinking Partner Conversation New Conversation
Paragraph 209 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 209, Sentence 1 0
No sentence-level conversations. Start one.

Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

New Thinking Partner Conversation New Conversation
Paragraph 210 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 210, Sentence 1 0
No sentence-level conversations. Start one.

Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

New Thinking Partner Conversation New Conversation
Paragraph 211 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 211, Sentence 1 0
No sentence-level conversations. Start one.

No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone. Amiodarone group experienced a higher likelihood of terminating VF/pVT within three shocks

New Thinking Partner Conversation New Conversation
Paragraph 212 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 212, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 212, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 212, Sentence 3 0
No sentence-level conversations. Start one.

0 Experimental Studies

New Thinking Partner Conversation New Conversation
Paragraph 213 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 213, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: Survival to discharge

New Thinking Partner Conversation New Conversation
Paragraph 214 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 214, Sentence 1 0
No sentence-level conversations. Start one.

3 Clinical Trials

New Thinking Partner Conversation New Conversation
Paragraph 215 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 215, Sentence 1 0
No sentence-level conversations. Start one.

Kudenchuk et al., 2016: Amiodarone, lidocaine, or placebo in OOHCA

New Thinking Partner Conversation New Conversation
Paragraph 216 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 216, Sentence 1 0
No sentence-level conversations. Start one.

Randomized, double blind trial of adults with non-traumatic OOHCA and shock refractory VF or PVT (shock refractory: persistent or recurrent shockable rhythm after one or more shocks anytime during resuscitation). Patients then randomized to receive amiodarone, lidocaine, or placebo after a vasopressor

New Thinking Partner Conversation New Conversation
Paragraph 217 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 217, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 217, Sentence 2 0
No sentence-level conversations. Start one.

Neither amiodarone nor lidocaine resulted in a higher survivor or favorable neuro outcome than placebo

New Thinking Partner Conversation New Conversation
Paragraph 218 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 218, Sentence 1 0
No sentence-level conversations. Start one.

With witnessed arrest, lidocaine and amiodarone had significantly higher survival than placebo

New Thinking Partner Conversation New Conversation
Paragraph 219 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 219, Sentence 1 0
No sentence-level conversations. Start one.

Kudenchuk et al., 2017: Antiarrhythmic drugs for nonshockable turned shockable OOHCA

New Thinking Partner Conversation New Conversation
Paragraph 220 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 220, Sentence 1 0
No sentence-level conversations. Start one.

Adults with nontraumatic OOHCA and VF/PVT anytime after one or more shocks randomized to placebo, lidocaine, or amiodarone

New Thinking Partner Conversation New Conversation
Paragraph 221 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 221, Sentence 1 0
No sentence-level conversations. Start one.

3026 with VF/PVT and 1063 with nonshockable turned shockable

New Thinking Partner Conversation New Conversation
Paragraph 222 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 222, Sentence 1 0
No sentence-level conversations. Start one.

Non-statistically significant increase in survival (and improved neuro outcome) with amiodarone or lidocaine compared to placebo

New Thinking Partner Conversation New Conversation
Paragraph 223 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 223, Sentence 1 0
No sentence-level conversations. Start one.

Survival approached significance (p 0.08) for nonshockable turned shockable rhythms with amiodarone compared to placebo

New Thinking Partner Conversation New Conversation
Paragraph 224 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 224, Sentence 1 0
No sentence-level conversations. Start one.

Daye et al., 2020: Survival after IV versus IO amiodarone, lidocaine, or placebo in OOH shock-refractory cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 225 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 225, Sentence 1 0
No sentence-level conversations. Start one.

Same study population as previous study

New Thinking Partner Conversation New Conversation
Paragraph 226 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 226, Sentence 1 0
No sentence-level conversations. Start one.

Amiodarone and lidocaine associated with more survival to discharge and survival to hospital admission when administered IV, but not IO when compared to placebo

New Thinking Partner Conversation New Conversation
Paragraph 227 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 227, Sentence 1 0
No sentence-level conversations. Start one.

8 Observational Studies

New Thinking Partner Conversation New Conversation
Paragraph 228 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 228, Sentence 1 0
No sentence-level conversations. Start one.

Valdes et al., 2014: Outcomes associated with amiodarone and lidocaine in the treatment of in hospital pediatric cardiac arrest with pVT or VF

New Thinking Partner Conversation New Conversation
Paragraph 229 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 229, Sentence 1 0
No sentence-level conversations. Start one.

Retrospective cohort study for inpatient cardiac arrest in 889 patients

New Thinking Partner Conversation New Conversation
Paragraph 230 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 230, Sentence 1 0
No sentence-level conversations. Start one.

Lidocaine associated with improved ROSC and 24 hour survival but not hospital discharge. Amiodarone not associated with ROSC or survival

New Thinking Partner Conversation New Conversation
Paragraph 231 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 231, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 231, Sentence 2 0
No sentence-level conversations. Start one.

Pollak et al., 2006: The use of amiodarone for in hospital cardiac arrest at two tertiary care centres

New Thinking Partner Conversation New Conversation
Paragraph 232 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 232, Sentence 1 0
No sentence-level conversations. Start one.

374 charts retrospectively examined; shockable rhythms present in 95 patients

New Thinking Partner Conversation New Conversation
Paragraph 233 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 233, Sentence 1 0
No sentence-level conversations. Start one.

No difference in ROSC or survival between amiodarone and patients receiving only other antiarrhythmics (though amiodarone trended towards lower ROSC and survival)

New Thinking Partner Conversation New Conversation
Paragraph 234 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 234, Sentence 1 0
No sentence-level conversations. Start one.

Holmberg et al., 2020: Lidocaine versus amiodarone for pediatric in hospital cardiac arrest: an observational study

New Thinking Partner Conversation New Conversation
Paragraph 235 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 235, Sentence 1 0
No sentence-level conversations. Start one.

From registry, included children with IHCA with an initial or subsequent shockable rhythm and then matched based on a propensity score

New Thinking Partner Conversation New Conversation
Paragraph 236 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 236, Sentence 1 0
No sentence-level conversations. Start one.

No difference between lidocaine and amiodarone for survival, ROSC, or favorable neuro outcome

New Thinking Partner Conversation New Conversation
Paragraph 237 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 237, Sentence 1 0
No sentence-level conversations. Start one.

Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

New Thinking Partner Conversation New Conversation
Paragraph 238 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 238, Sentence 1 0
No sentence-level conversations. Start one.

Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

New Thinking Partner Conversation New Conversation
Paragraph 239 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 239, Sentence 1 0
No sentence-level conversations. Start one.

No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone.

New Thinking Partner Conversation New Conversation
Paragraph 240 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 240, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 240, Sentence 2 0
No sentence-level conversations. Start one.

Amino et al., 2015: Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24 hours survival in CPA patients: the SOS-KANTO 2012 study

New Thinking Partner Conversation New Conversation
Paragraph 241 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 241, Sentence 1 0
No sentence-level conversations. Start one.

Enrolled 500 adults with OOHCA who used a single antiarrhythmic for shock resistant VF/VT. Survival to admission significantly higher with amiodarone and nifekalant compared to lidocaine and 24 hour survival. ROSC not different between groups

New Thinking Partner Conversation New Conversation
Paragraph 242 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 242, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 242, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 242, Sentence 3 0
No sentence-level conversations. Start one.

Tagami et al., 2016: Amiodarone or nifekalant upon hospital arrival for refractory VF after OOHCA

New Thinking Partner Conversation New Conversation
Paragraph 243 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 243, Sentence 1 0
No sentence-level conversations. Start one.

Retrospective cohort study of adults with cardiogenic OOHCA and with VF on hospital arrival classified into amiodarone or nifekalant groups. From there, propensity matching occurred

New Thinking Partner Conversation New Conversation
Paragraph 244 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 244, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 244, Sentence 2 0
No sentence-level conversations. Start one.

Amiodarone significantly less likely to be admitted to hospital but no difference in in hospital mortality

New Thinking Partner Conversation New Conversation
Paragraph 245 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 245, Sentence 1 0
No sentence-level conversations. Start one.

Tagami et al., 2016: Amiodarone compared with lidocaine for OOHCA with refractory VF on hospital arrival: a nationwide database study

New Thinking Partner Conversation New Conversation
Paragraph 246 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 246, Sentence 1 0
No sentence-level conversations. Start one.

Same procedure as above but categorized into amiodarone or lidocaine groups

New Thinking Partner Conversation New Conversation
Paragraph 247 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 247, Sentence 1 0
No sentence-level conversations. Start one.

No difference in survival to hospital discharge

New Thinking Partner Conversation New Conversation
Paragraph 248 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 248, Sentence 1 0
No sentence-level conversations. Start one.

Huang et al., 2017: Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with OOHCA: a nationwide cohort study

New Thinking Partner Conversation New Conversation
Paragraph 249 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 249, Sentence 1 0
No sentence-level conversations. Start one.

Repository for insurance claims in Taiwan was searched. Included all non-traumatic adults receiving shock and CPR immediately or within 6 hours of ER arrival

New Thinking Partner Conversation New Conversation
Paragraph 250 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 250, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 250, Sentence 2 0
No sentence-level conversations. Start one.

Better survival to ICU admission, discharge, and 1 year survival when given both lidocaine and amiodarone (over amiodarone, then lidocaine, then neither). In intergroup comparisons, no difference between patients given one or both medications

New Thinking Partner Conversation New Conversation
Paragraph 251 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 251, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 251, Sentence 2 0
No sentence-level conversations. Start one.

4 Experimental Studies

New Thinking Partner Conversation New Conversation
Paragraph 252 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 252, Sentence 1 0
No sentence-level conversations. Start one.

Ji et al., 2010: Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 253 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 253, Sentence 1 0
No sentence-level conversations. Start one.

4 minutes of untreated VF in 36 pigs randomized to amiodarone, placebo, or nifekalant. CPR initiated after drug admin and defibrillation attempted 2 minutes later

New Thinking Partner Conversation New Conversation
Paragraph 254 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 254, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 254, Sentence 2 0
No sentence-level conversations. Start one.

Nifekalant and amiodarone decreased number of shocks, defibrillation energy, epi dose, and duration of CPR. Higher ROSC and 24 hour survival in both groups. Improved postresuscitation myocardial dysfunction with treatment

New Thinking Partner Conversation New Conversation
Paragraph 255 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 255, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 255, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 255, Sentence 3 0
No sentence-level conversations. Start one.

Glover et al., 2013: Dronedarone and captisol enabled amiodarone in an experimental cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 256 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 256, Sentence 1 0
No sentence-level conversations. Start one.

42 pigs had induced VF, CPR for 3 minutes and then randomized to receive placebo, amiodarone, or dronedarone, followed by defibrillation and continued CPR

New Thinking Partner Conversation New Conversation
Paragraph 257 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 257, Sentence 1 0
No sentence-level conversations. Start one.

No difference in survival with amiodarone admin compared to control. Worse survival with dronedarone

New Thinking Partner Conversation New Conversation
Paragraph 258 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 258, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 258, Sentence 2 0
No sentence-level conversations. Start one.

Karlis et al., 2015: Nifekalant versus amiodarone in the treatment of cardiac arrest: an experimental study in a swine model of prolonged VF

New Thinking Partner Conversation New Conversation
Paragraph 259 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 259, Sentence 1 0
No sentence-level conversations. Start one.

8 minutes of untreated VF followed by bolus of epi and either nifekalant, amiodarone, or saline in pigs. Then CPR and defibrillation after 2 minutes

New Thinking Partner Conversation New Conversation
Paragraph 260 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 260, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 260, Sentence 2 0
No sentence-level conversations. Start one.

Higher survival with nifekalant v amiodarone and saline. Higher SAP, DAP, and CPP with nifekalant. Number of shocks needed, time to ROSC, and epi dose higher with amiodarone. No difference in 48 hour survival between control and amiodarone

New Thinking Partner Conversation New Conversation
Paragraph 261 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 261, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 261, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 261, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 261, Sentence 4 0
No sentence-level conversations. Start one.

Zoerner et al., 2014: Resuscitation with amiodarone increases survival after hemorrhage and VF in pigs

New Thinking Partner Conversation New Conversation
Paragraph 262 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 262, Sentence 1 0
No sentence-level conversations. Start one.

18 anesthetized piglets bled 30% blood volume to MAP of 35 mmHg followed by 4 minutes of VF and 11 minutes of open chest CPR. At 4 minutes received either amiodarone or saline. Both groups received hypertonic-hyperoncotic solution and vasopressin at this time. Defibrillation attempted from 7 min of cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 263 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 263, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 263, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 263, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 263, Sentence 4 0
No sentence-level conversations. Start one.

Greater 3 hour survival in amiodarone group; also had lower HR and better SAP, DAP, and MAP. Lower troponin I and higher UOP

New Thinking Partner Conversation New Conversation
Paragraph 264 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 264, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 264, Sentence 2 0
No sentence-level conversations. Start one.

Outcome: ROSC

New Thinking Partner Conversation New Conversation
Paragraph 265 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 265, Sentence 1 0
No sentence-level conversations. Start one.

1 Clinical Trial

New Thinking Partner Conversation New Conversation
Paragraph 266 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 266, Sentence 1 0
No sentence-level conversations. Start one.

Kudenchuk et al., 2017: Antiarrhythmic drugs for nonshockable turned shockable OOHCA

New Thinking Partner Conversation New Conversation
Paragraph 267 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 267, Sentence 1 0
No sentence-level conversations. Start one.

Adults with nontraumatic OOHCA and VF/PVT anytime after one or more shocks randomized to placebo, lidocaine, or amiodarone

New Thinking Partner Conversation New Conversation
Paragraph 268 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 268, Sentence 1 0
No sentence-level conversations. Start one.

3026 with VF/PVT and 1063 with nonshockable turned shockable

New Thinking Partner Conversation New Conversation
Paragraph 269 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 269, Sentence 1 0
No sentence-level conversations. Start one.

No difference in ROSC

New Thinking Partner Conversation New Conversation
Paragraph 270 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 270, Sentence 1 0
No sentence-level conversations. Start one.

2 Observational Studies

New Thinking Partner Conversation New Conversation
Paragraph 271 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 271, Sentence 1 0
No sentence-level conversations. Start one.

Valdes et al., 2014: Outcomes associated with amiodarone and lidocaine in the treatment of in hospital pediatric cardiac arrest with pVT or VF

New Thinking Partner Conversation New Conversation
Paragraph 272 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 272, Sentence 1 0
No sentence-level conversations. Start one.

Retrospective cohort study for inpatient cardiac arrest in 889 patients

New Thinking Partner Conversation New Conversation
Paragraph 273 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 273, Sentence 1 0
No sentence-level conversations. Start one.

Lidocaine associated with improved ROSC and 24 hour survival but not hospital discharge. Amiodarone not associated with ROSC or survival

New Thinking Partner Conversation New Conversation
Paragraph 274 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 274, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 274, Sentence 2 0
No sentence-level conversations. Start one.

Pollak et al., 2006: The use of amiodarone for in hospital cardiac arrest at two tertiary care centres

New Thinking Partner Conversation New Conversation
Paragraph 275 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 275, Sentence 1 0
No sentence-level conversations. Start one.

374 charts retrospectively examined; shockable rhythms present in 95 patients

New Thinking Partner Conversation New Conversation
Paragraph 276 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 276, Sentence 1 0
No sentence-level conversations. Start one.

No difference in ROSC or survival between amiodarone and patients receiving only other antiarrhythmics (though amiodarone trended towards lower ROSC and survival)

New Thinking Partner Conversation New Conversation
Paragraph 277 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 277, Sentence 1 0
No sentence-level conversations. Start one.

Salcido et al., 2018: Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial

New Thinking Partner Conversation New Conversation
Paragraph 278 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 278, Sentence 1 0
No sentence-level conversations. Start one.

Secondary analysis of the ALPS trial listed above

New Thinking Partner Conversation New Conversation
Paragraph 279 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 279, Sentence 1 0
No sentence-level conversations. Start one.

ALPS treatment group (placebo, lidocaine, or amiodarone) was not associated with rearrest

New Thinking Partner Conversation New Conversation
Paragraph 280 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 280, Sentence 1 0
No sentence-level conversations. Start one.

Holmberg et al., 2020: Lidocaine versus amiodarone for pediatric in hospital cardiac arrest: an observational study

New Thinking Partner Conversation New Conversation
Paragraph 281 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 281, Sentence 1 0
No sentence-level conversations. Start one.

From registry, included children with IHCA with an initial or subsequent shockable rhythm and then matched based on a propensity score

New Thinking Partner Conversation New Conversation
Paragraph 282 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 282, Sentence 1 0
No sentence-level conversations. Start one.

No difference between lidocaine and amiodarone for survival, ROSC, or favorable neuro outcome

New Thinking Partner Conversation New Conversation
Paragraph 283 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 283, Sentence 1 0
No sentence-level conversations. Start one.

Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

New Thinking Partner Conversation New Conversation
Paragraph 284 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 284, Sentence 1 0
No sentence-level conversations. Start one.

Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

New Thinking Partner Conversation New Conversation
Paragraph 285 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 285, Sentence 1 0
No sentence-level conversations. Start one.

No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone.

New Thinking Partner Conversation New Conversation
Paragraph 286 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 286, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 286, Sentence 2 0
No sentence-level conversations. Start one.

Amino et al., 2015: Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24 hours survival in CPA patients: the SOS-KANTO 2012 study

New Thinking Partner Conversation New Conversation
Paragraph 287 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 287, Sentence 1 0
No sentence-level conversations. Start one.

Enrolled 500 adults with OOHCA who used a single antiarrhythmic for shock resistant VF/VT. Survival to admission significantly higher with amiodarone and nifekalant compared to lidocaine and 24 hour survival. ROSC not different between groups

New Thinking Partner Conversation New Conversation
Paragraph 288 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 288, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 288, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 288, Sentence 3 0
No sentence-level conversations. Start one.

7 Experimental Studies

New Thinking Partner Conversation New Conversation
Paragraph 289 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 289, Sentence 1 0
No sentence-level conversations. Start one.

Ji et al., 2010: Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 290 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 290, Sentence 1 0
No sentence-level conversations. Start one.

4 minutes of untreated VF in 36 pigs randomized to amiodarone, placebo, or nifekalant. CPR initiated after drug admin and defibrillation attempted 2 minutes later

New Thinking Partner Conversation New Conversation
Paragraph 291 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 291, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 291, Sentence 2 0
No sentence-level conversations. Start one.

Nifekalant and amiodarone decreased number of shocks, defibrillation energy, epi dose, and duration of CPR. Higher ROSC and 24 hour survival in both groups. Improved postresuscitation myocardial dysfunction with treatment

New Thinking Partner Conversation New Conversation
Paragraph 292 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 292, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 292, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 292, Sentence 3 0
No sentence-level conversations. Start one.

Zoerner et al., 2014: Resuscitation with amiodarone increases survival after hemorrhage and VF in pigs

New Thinking Partner Conversation New Conversation
Paragraph 293 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 293, Sentence 1 0
No sentence-level conversations. Start one.

18 anesthetized piglets bled 30% blood volume to MAP of 35 mmHg followed by 4 minutes of VF and 11 minutes of open chest CPR. At 4 minutes received either amiodarone or saline. Both groups received hypertonic-hyperoncotic solution and vasopressin at this time. Defibrillation attempted from 7 min of cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 294 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 294, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 294, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 294, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 294, Sentence 4 0
No sentence-level conversations. Start one.

ROSC effects did not achieve statistical significant difference. Pigs in control group needed more vasopressin doses to achieve ROSC

New Thinking Partner Conversation New Conversation
Paragraph 295 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 295, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 295, Sentence 2 0
No sentence-level conversations. Start one.

Karlis et al., 2015: Nifekalant versus amiodarone in the treatment of cardiac arrest: an experimental study in a swine model of prolonged VF

New Thinking Partner Conversation New Conversation
Paragraph 296 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 296, Sentence 1 0
No sentence-level conversations. Start one.

8 minutes of untreated VF followed by bolus of epi and either nifekalant, amiodarone, or saline in pigs. Then CPR and defibrillation after 2 minutes

New Thinking Partner Conversation New Conversation
Paragraph 297 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 297, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 297, Sentence 2 0
No sentence-level conversations. Start one.

Number of shocks needed, time to ROSC, and epi dose higher with amiodarone. No difference in 48 hour survival between control and amiodarone or ROSC

New Thinking Partner Conversation New Conversation
Paragraph 298 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 298, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 298, Sentence 2 0
No sentence-level conversations. Start one.

Stoner et al., 2003: Amiodarone and bretylium in the treatment of hypothermic VF in a canine model

New Thinking Partner Conversation New Conversation
Paragraph 299 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 299, Sentence 1 0
No sentence-level conversations. Start one.

30 dogs anesthetized, cooled, and VF induced. CPR initiated (no epi) and randomized to receive amiodarone, bretylium or placebo. After 10 minutes, up to three shocks administered

New Thinking Partner Conversation New Conversation
Paragraph 300 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 300, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 300, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 300, Sentence 3 0
No sentence-level conversations. Start one.

No difference in ROSC between groups

New Thinking Partner Conversation New Conversation
Paragraph 301 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 301, Sentence 1 0
No sentence-level conversations. Start one.

Wira et al., 2006: Application of normothermic cardiac arrest algorithms to hypothermic cardiac arrest in a canine model

New Thinking Partner Conversation New Conversation
Paragraph 302 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 302, Sentence 1 0
No sentence-level conversations. Start one.

21 dogs cooled to VF or VF induced if necessary. Treatment group received epi, defibrillation, and amiodarone. Not blinded

New Thinking Partner Conversation New Conversation
Paragraph 303 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 303, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 303, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 303, Sentence 3 0
No sentence-level conversations. Start one.

CPP increased with amiodarone/epi administration and improved ROSC

New Thinking Partner Conversation New Conversation
Paragraph 304 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 304, Sentence 1 0
No sentence-level conversations. Start one.

Anastasiou-Nana et al., 1994: Effects of amiodarone on refractory VF in acute myocardial infarction: experimental study

New Thinking Partner Conversation New Conversation
Paragraph 305 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 305, Sentence 1 0
No sentence-level conversations. Start one.

AMI induced in 60 dogs via ligation. Dogs that developed VF were treated with lidocaine, epi, and 5 shocks. Refractory dogs randomized to receive epi, lidocaine, and counter shocks or amiodarone and countershocks

New Thinking Partner Conversation New Conversation
Paragraph 306 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 306, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 306, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 306, Sentence 3 0
No sentence-level conversations. Start one.

Defibrillation significantly higher in amiodarone group

New Thinking Partner Conversation New Conversation
Paragraph 307 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 307, Sentence 1 0
No sentence-level conversations. Start one.

Wiesmann et al., 2017: Dantrolene versus amiodarone for CPR: a randomized double blinded experimental stuy

New Thinking Partner Conversation New Conversation
Paragraph 308 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 308, Sentence 1 0
No sentence-level conversations. Start one.

VF induced in anesthetized pigs. After 8 min untreated, CPR started and randomized to amiodarone, dantrolene, or slaine. After 4 minutes, defibrillation attempted

New Thinking Partner Conversation New Conversation
Paragraph 309 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 309, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 309, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 309, Sentence 3 0
No sentence-level conversations. Start one.

No difference in ROSC, persistent ROSC, or shocks until ROSC between groups

New Thinking Partner Conversation New Conversation
Paragraph 310 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 310, Sentence 1 0
No sentence-level conversations. Start one.

Outcome: Surrogate markers of perfusion

New Thinking Partner Conversation New Conversation
Paragraph 311 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 311, Sentence 1 0
No sentence-level conversations. Start one.

0 Clinical Trials

New Thinking Partner Conversation New Conversation
Paragraph 312 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 312, Sentence 1 0
No sentence-level conversations. Start one.

1 Observational Studies

New Thinking Partner Conversation New Conversation
Paragraph 313 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 313, Sentence 1 0
No sentence-level conversations. Start one.

Wang et al., 2020: Outcomes associated with amiodarone and lidocaine for the treatment for adult IHCA with shock refractory pulseless ventricular tachyarrhythmia

New Thinking Partner Conversation New Conversation
Paragraph 314 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 314, Sentence 1 0
No sentence-level conversations. Start one.

Included 130 patients with IHCA and VF/pVT requiring more than one defibrillation attempt

New Thinking Partner Conversation New Conversation
Paragraph 315 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 315, Sentence 1 0
No sentence-level conversations. Start one.

No control group. No difference in ROSC, survival or favorable neuro outcome for lidocaine v amiodarone. Amiodarone group experienced a higher likelihood of terminating VF/pVT within three shocks

New Thinking Partner Conversation New Conversation
Paragraph 316 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 316, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 316, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 316, Sentence 3 0
No sentence-level conversations. Start one.

11 Experimental Studies

New Thinking Partner Conversation New Conversation
Paragraph 317 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 317, Sentence 1 0
No sentence-level conversations. Start one.

Stoner et al., 2003: Amiodarone and bretylium in the treatment of hypothermic VF in a canine model

New Thinking Partner Conversation New Conversation
Paragraph 318 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 318, Sentence 1 0
No sentence-level conversations. Start one.

30 dogs anesthetized, cooled, and VF induced. CPR initiated (no epi) and randomized to receive amiodarone, bretylium or placebo. After 10 minutes, up to three shocks administered

New Thinking Partner Conversation New Conversation
Paragraph 319 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 319, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 319, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 319, Sentence 3 0
No sentence-level conversations. Start one.

Amiodarone lowered CPP but did not reach statistical significance

New Thinking Partner Conversation New Conversation
Paragraph 320 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 320, Sentence 1 0
No sentence-level conversations. Start one.

Wira et al., 2006: Application of normothermic cardiac arrest algorithms to hypothermic cardiac arrest in a canine model

New Thinking Partner Conversation New Conversation
Paragraph 321 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 321, Sentence 1 0
No sentence-level conversations. Start one.

21 dogs cooled to VF or VF induced if necessary. Treatment group received epi, defibrillation, and amiodarone. Not blinded

New Thinking Partner Conversation New Conversation
Paragraph 322 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 322, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 322, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 322, Sentence 3 0
No sentence-level conversations. Start one.

CPP increased with amiodarone/epi administration and improved ROSC

New Thinking Partner Conversation New Conversation
Paragraph 323 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 323, Sentence 1 0
No sentence-level conversations. Start one.

Ji et al., 2010: Comparison of the efficacy of nifekalant and amiodarone in a porcine model of cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 324 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 324, Sentence 1 0
No sentence-level conversations. Start one.

4 minutes of untreated VF in 36 pigs randomized to amiodarone, placebo, or nifekalant. CPR initiated after drug admin and defibrillation attempted 2 minutes later

New Thinking Partner Conversation New Conversation
Paragraph 325 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 325, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 325, Sentence 2 0
No sentence-level conversations. Start one.

Nifekalant and amiodarone decreased number of shocks, defibrillation energy, epi dose, and duration of CPR. Improved postresuscitation myocardial dysfunction with treatment. Amiodarone decreased HR, arterial BP, and CPP

New Thinking Partner Conversation New Conversation
Paragraph 326 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 326, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 326, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 326, Sentence 3 0
No sentence-level conversations. Start one.

Glover et al., 2013: Dronedarone and captisol enabled amiodarone in an experimental cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 327 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 327, Sentence 1 0
No sentence-level conversations. Start one.

42 pigs had induced VF, CPR for 3 minutes and then randomized to receive placebo, amiodarone, or dronedarone, followed by defibrillation and continued CPR

New Thinking Partner Conversation New Conversation
Paragraph 328 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 328, Sentence 1 0
No sentence-level conversations. Start one.

No effect on surrogate markers of perfusion

New Thinking Partner Conversation New Conversation
Paragraph 329 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 329, Sentence 1 0
No sentence-level conversations. Start one.

Anastasiou-Nana et al., 1994: Effects of amiodarone on refractory VF in acute myocardial infarction: experimental study

New Thinking Partner Conversation New Conversation
Paragraph 330 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 330, Sentence 1 0
No sentence-level conversations. Start one.

AMI induced in 60 dogs via ligation. Dogs that developed VF were treated with lidocaine, epi, and 5 shocks. Refractory dogs randomized to receive epi, lidocaine, and counter shocks or amiodarone and countershocks

New Thinking Partner Conversation New Conversation
Paragraph 331 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 331, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 331, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 331, Sentence 3 0
No sentence-level conversations. Start one.

Defibrillation significantly higher in amiodarone group. Worse markers of perfusion in amiodarone group

New Thinking Partner Conversation New Conversation
Paragraph 332 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 332, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 332, Sentence 2 0
No sentence-level conversations. Start one.

Karlis et al., 2015: Nifekalant versus amiodarone in the treatment of cardiac arrest: an experimental study in a swine model of prolonged VF

New Thinking Partner Conversation New Conversation
Paragraph 333 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 333, Sentence 1 0
No sentence-level conversations. Start one.

8 minutes of untreated VF followed by bolus of epi and either nifekalant, amiodarone, or saline in pigs. Then CPR and defibrillation after 2 minutes

New Thinking Partner Conversation New Conversation
Paragraph 334 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 334, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 334, Sentence 2 0
No sentence-level conversations. Start one.

Higher SAP, DAP, and CPP with nifekalant. Number of shocks needed, time to ROSC, and epi dose higher with amiodarone.

New Thinking Partner Conversation New Conversation
Paragraph 335 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 335, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 335, Sentence 2 0
No sentence-level conversations. Start one.

Zoerner et al., 2014: Resuscitation with amiodarone increases survival after hemorrhage and VF in pigs

New Thinking Partner Conversation New Conversation
Paragraph 336 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 336, Sentence 1 0
No sentence-level conversations. Start one.

18 anesthetized piglets bled 30% blood volume to MAP of 35 mmHg followed by 4 minutes of VF and 11 minutes of open chest CPR. At 4 minutes received either amiodarone or saline. Both groups received hypertonic-hyperoncotic solution and vasopressin at this time. Defibrillation attempted from 7 min of cardiac arrest

New Thinking Partner Conversation New Conversation
Paragraph 337 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 337, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 337, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 337, Sentence 3 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 337, Sentence 4 0
No sentence-level conversations. Start one.

Greater 3 hour survival in amiodarone group; also had lower HR and better SAP, DAP, and MAP. Lower troponin I and higher UOP

New Thinking Partner Conversation New Conversation
Paragraph 338 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 338, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 338, Sentence 2 0
No sentence-level conversations. Start one.

Frame, 1989: The effect of chronic oral and acute IV amiodarone administration on ventricular defibrillation threshold using implanted electrodes in dogs

New Thinking Partner Conversation New Conversation
Paragraph 339 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 339, Sentence 1 0
No sentence-level conversations. Start one.

VF induced and then defibrillation following oral and IV amiodarone administration

New Thinking Partner Conversation New Conversation
Paragraph 340 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 340, Sentence 1 0
No sentence-level conversations. Start one.

Oral amiodarone increased the fibrillation threshold. No change with IV administration. Not directly relevant to PICO, but provides important info tangential to it (amiodarone probably does not make it harder to defibrillate)

New Thinking Partner Conversation New Conversation
Paragraph 341 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 341, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 341, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 341, Sentence 3 0
No sentence-level conversations. Start one.

Fain et al., 1987: Effects of acute IV and chronic oral amiodarone on defibrillation energy requirements

New Thinking Partner Conversation New Conversation
Paragraph 342 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 342, Sentence 1 0
No sentence-level conversations. Start one.

VF induced and then defibrillation following oral and IV amiodarone administration

New Thinking Partner Conversation New Conversation
Paragraph 343 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 343, Sentence 1 0
No sentence-level conversations. Start one.

Oral amiodarone increased the fibrillation threshold. No change with IV administration. Not directly relevant to PICO, but provides important info tangential to it (amiodarone probably does not make it harder to defibrillate)

New Thinking Partner Conversation New Conversation
Paragraph 344 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 344, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 344, Sentence 2 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 344, Sentence 3 0
No sentence-level conversations. Start one.

Paiva et al, 2003: Effect of amiodarone on haemodynamics during CPR in a canine model of resistant VF

New Thinking Partner Conversation New Conversation
Paragraph 345 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 345, Sentence 1 0
No sentence-level conversations. Start one.

30 dogs with 8 minutes untreated VF, defibrillation attempted and CPR started. Resistant dogs randomized to epi, amiodarone, or both

New Thinking Partner Conversation New Conversation
Paragraph 346 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 346, Sentence 1 0
No sentence-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 346, Sentence 2 0
No sentence-level conversations. Start one.

SAP, DAP, and CPP all lower in amiodarone alone group

New Thinking Partner Conversation New Conversation
Paragraph 347 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 347, Sentence 1 0
No sentence-level conversations. Start one.

Arrendondo et al., 1986: Effect of amiodarone on ventricular fibrillation and defibrillation thresholds in the canine heart under normal and ischemic conditions

New Thinking Partner Conversation New Conversation
Paragraph 348 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 348, Sentence 1 0
No sentence-level conversations. Start one.

11 dogs with VF during control, drug (amiodarone), and coronary occlusion phases

New Thinking Partner Conversation New Conversation
Paragraph 349 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 349, Sentence 1 0
No sentence-level conversations. Start one.

Amiodarone led to successful defibrillation in 7/8 dogs compared to 1/7 in the control group P<0.005)

New Thinking Partner Conversation New Conversation
Paragraph 350 0
No paragraph-level conversations. Start one.
New Thinking Partner Conversation New Conversation
Paragraph 350, Sentence 1 0
No sentence-level conversations. Start one.

DMU Timestamp: July 13, 2023 21:18

General Document Comments 0
New Thinking Partner Conversation Start a new Document-level conversation

profile_photo
Jul 17
Rebecca W Rebecca W (Jul 17 2023 8:37PM) : The previous comment does not recommend lidocaine use and then this PICO starts with "if lidocaine is unavailable"
profile_photo
Jul 17
Dan F Dan F (Jul 17 2023 9:56PM) : Please clarify your question. [Edited] more

Hi Rebecca! Can you please clarify what you mean by “the previous comment?” ALS-01 suggests that lidocaine can be used in dogs but probably shouldn’t be used in cats. This PICO suggests that if lidocaine is not available, you could use amiodarone in dogs, but lidocaine is preferred. Please let us know what you mean here. Thanks!

Image
0 comments, 0 areas
add area
add comment
change display
Video
add comment

Quickstart: Commenting and Sharing

How to Comment
  • Click icons on the left to see existing comments.
  • Desktop/Laptop: double-click any text, highlight a section of an image, or add a comment while a video is playing to start a new conversation.
    Tablet/Phone: single click then click on the "Start One" link (look right or below).
  • Click "Reply" on a comment to join the conversation.
How to Share Documents
  1. "Upload" a new document.
  2. "Invite" others to it.

Logging in, please wait... Blue_on_grey_spinner